Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | ESRRA | P11474 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14620533 | 0.82 | ADRB3 (0.46) | TRPV1ADRB3CYP19A1NPC1RAB9A | |
| SCHEMBL11918930 | 0.82 | ADRB3 (0.46) | TRPV1ADRB3CYP19A1NPC1RAB9A | |
| SCHEMBL4816663 | 0.82 | CYP19A1 (0.48) | TRPV1ADRB3CYP19A1ESRRANPC1 | |
| SCHEMBL9281429 | 0.76 | ADRB3 (0.66) | ADRB3 | |
| SCHEMBL9906203 | 0.76 | ADRB3 (0.48) | ADRB3NPC1 | |
| SCHEMBL1577102 | 0.76 | ADRB3 (0.66) | ADRB3 | |
| SCHEMBL9281433 | 0.76 | ADRB3 (0.66) | ADRB3 | |
| SCHEMBL11918925 | 0.74 | CREBBP (0.50) | CYP19A1ESRRAPTPN1NPC1RAB9A | |
| SCHEMBL11915675 | 0.73 | SMN1; SMN2 (0.56) | CYP19A1ESRRAPTPN1SLC2A1NPC1 | |
| SCHEMBL8604748 | 0.73 | CYP19A1 (0.51) | TRPV1ADRB3CYP19A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198330-B2 | Therapeutic or prophylactic agent for diabetes, obesity, dyslipidemia or metabolic syndrome comprising benzylamine derivative or pharmaceutically acceptable acid addition salt thereof | TORAY INDUSTRIES, INC. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110124733-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR DIABETES, OBESITY, DYSLIPIDEMIA OR METABOLIC SYNDROME COMPRISING BENZYLAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID | TORAY INDUSTRIES, INC. (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124733-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR DIABETES, OBESITY, DYSLIPIDEMIA OR METABOLIC SYNDROME COMPRISING BENZYLAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID | GPR119, LIPC, LIPA | TRPV1 843/4885ADRB3 64/4885CYP19A1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.